Smart-Money SignalNeutral · 54/100— Insiders are net buyers over 90 days ($10.0M, 3 buys vs 0 sales)
Net Income-$51.6M
EPS$-2.42
Market Cap$1.4B
Price Performance
Historical data including institutional events
Company Profile
H
Heather Turner
CEO & Executive Director
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation.
The company was incorporated in 2015 and is headquartered in New York, New York.
